Chenjie Zeng, PhD, MPH; Lisa A. Bastarache, MS; Ran Tao, PhD; et al.
free access
JAMA Oncol. 2022;8(6):835-844. doi:10.1001/jamaoncol.2022.0373
This phenome-wide association study uses phenotypic data derived from health records in 3 cohorts to investigate a broad range of phenotypes associated with hereditary cancer genes.
David A. Palma, MD, PhD; Eitan Prisman, MD; Eric Berthelet, MD; et al.
free access
has audio
JAMA Oncol. 2022;8(6):845-851. doi:10.1001/jamaoncol.2022.0615
This randomized clinical trial examines a primary radiotherapy approach vs a primary transoral surgical approach in treatment deescalation for HPV-related oropharyngeal squamous cell carcinoma.
-
Podcast:
Treatment Deescalation With Radiotherapy vs Transoral Surgery for HPV-Associated Oropharyngeal Squamous Cell Carcinoma
-
Invited Commentary
The ORATOR Trials Have Spoken—Where Do We Go From Here?
Sewit Teckie, MD; Neil D. Gross, MD
JAMA Oncol
Eric Leung, MD, MSc; Adam P. Gladwish, MD, MSc; Melanie Davidson, PhD; et al.
free access
JAMA Oncol. 2022;8(6):853-861. doi:10.1001/jamaoncol.2022.0362
This multicenter phase 1/2 nonrandomized controlled trial describes the physician-reported acute genitourinary and gastrointestinal toxic effects and patient-reported quality-of-life changes associated with undergoing stereotactic hypofractionated adjuvant radiation therapy of the pelvis for treatment of uterine cancer.
-
Invited Commentary
Are We Finally Ready for the Widespread Adoption of Stereotactic Radiation in Gynecologic Cancers?
Vonetta M. Williams, MD, PhD; Onyinye Balogun, MD, MSc; Kaled Alektiar, MD
JAMA Oncol
Catalina Malinowski, MPH, CHES, CHW; Xiudong Lei, PhD; Hui Zhao, PhD; et al.
free access
JAMA Oncol. 2022;8(6):863-870. doi:10.1001/jamaoncol.2022.0159
This cross-sectional study examines the association between Medicaid expansion and mortality disparities among racial and ethnic minority patients with de novo stage IV breast cancer.
Yukihide Momozawa, PhD; Rumi Sasai, MA; Yoshiaki Usui, MD; et al.
open access
JAMA Oncol. 2022;8(6):871-878. doi:10.1001/jamaoncol.2022.0476
This case-control study examines the association of BRCA1 and BRCA2 pathogenic variants with additional cancer types and their clinical characteristics in 100 914 Japanese individuals across 14 cancer types.
Joseph N. Samuel, PharmD, MSc; Christopher M. Booth, MD; Elizabeth Eisenhauer, MD; et al.
free access
JAMA Oncol. 2022;8(6):879-886. doi:10.1001/jamaoncol.2022.0864
This cohort study assesses whether cancer drug trials that show improvement in overall survival or progression-free survival also improve global quality of life in patients with cancer and how unchanged or detrimental quality-of-life outcomes are reported in trial publications.
Reshma Jagsi, MD, DPhil; Kent A. Griffith, MS, MPH; Frank Vicini, MD; et al.
free access
JAMA Oncol. 2022;8(6):887-894. doi:10.1001/jamaoncol.2022.0114
This cohort study examines patient-reported outcomes of patients with breast cancer who received radiotherapy and their physicians’ Common Toxicity Criteria for Adverse Events assessments to assess underrecognition of symptoms.
Megan A. Clarke, PhD, MHS; Susan S. Devesa, PhD, MHS; Anne Hammer, MD, PhD; et al.
free access
JAMA Oncol. 2022;8(6):895-903. doi:10.1001/jamaoncol.2022.0009
This cohort study analyzes histologic subtype- and stage-specific uterine cancer mortality rates by race and ethnicity.